October 11-15, 2023, AACR- NCI- EORCT International Conference On Molecular Targets And Cancer Therapeutics

1) Identification of Paralogue Selective Degraders Of SMARCA2 And SMARCA4 for the Treatment of Various Cancers2) Discovery of Potent and Paralogue Selective PROTAC Degraders of CBP or P300 Proteins for

September 26-28, 2023, Discovery On Target

1) Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion and Therapeutic Resistance2) Targeting CBP/P300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy

June 8-11, 2023, European Hematology Association

1) A Phase 1, Open Label, Dose Escalation, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR-103 in Patients with Relapsed Advanced Malignancies (BHARAT-1)

April 14 – 19, 2023, AACR

1) Generation of Profound Anti-Tumor Immunity by AUR-109, A Spectrum-Selective Tyrosine Kinase Inhibitor, Either as a Single Agent or in Combination with Immune Checkpoint Inhibitors2) A Highly Differentiated A2AR Inhibitor

April 10-13, 2023, Drug Discovery Chemistry

1) Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy